TWI703214B - 具拮抗ｐｄ-１功能的適體分子於癌症治療相關之應用 - Google Patents

具拮抗ｐｄ-１功能的適體分子於癌症治療相關之應用 Download PDF

Info

Publication number
TWI703214B
TWI703214B TW104124956A TW104124956A TWI703214B TW I703214 B TWI703214 B TW I703214B TW 104124956 A TW104124956 A TW 104124956A TW 104124956 A TW104124956 A TW 104124956A TW I703214 B TWI703214 B TW I703214B
Authority
TW
Taiwan
Prior art keywords
aptamer
seq
nucleic acid
dimer
peg
Prior art date
Application number
TW104124956A
Other languages
English (en)
Chinese (zh)
Other versions
TW201617449A (zh
Inventor
楊泮池
張翼中
賴薇云
Original Assignee
中央研究院
國立台灣大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中央研究院, 國立台灣大學 filed Critical 中央研究院
Publication of TW201617449A publication Critical patent/TW201617449A/zh
Application granted granted Critical
Publication of TWI703214B publication Critical patent/TWI703214B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW104124956A 2014-07-31 2015-07-31 具拮抗ｐｄ-１功能的適體分子於癌症治療相關之應用 TWI703214B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462031427P 2014-07-31 2014-07-31
US62/031,427 2014-07-31

Publications (2)

Publication Number Publication Date
TW201617449A TW201617449A (zh) 2016-05-16
TWI703214B true TWI703214B (zh) 2020-09-01

Family

ID=55218360

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104124956A TWI703214B (zh) 2014-07-31 2015-07-31 具拮抗ｐｄ-１功能的適體分子於癌症治療相關之應用

Country Status (8)

Country Link
US (1) US10329570B2 (enExample)
EP (1) EP3174985A4 (enExample)
JP (1) JP6680760B2 (enExample)
KR (1) KR20170055474A (enExample)
CN (1) CN107002083A (enExample)
CA (1) CA2956718A1 (enExample)
TW (1) TWI703214B (enExample)
WO (1) WO2016019270A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42459A (fr) 2015-07-16 2018-05-23 Bioxcel Therapeutics Inc Nouvelle approche pour le traitement du cancer par immunomodulation
CN109312347A (zh) 2016-02-19 2019-02-05 希望之城 双特异性适配子
WO2018048888A1 (en) * 2016-09-06 2018-03-15 The Methodist Hospital System Pd-1 specific aptamers
CN109982707A (zh) * 2016-09-16 2019-07-05 杜克大学 血管性血友病因子（vwf）靶向剂及其使用方法
CN107794267B (zh) * 2017-03-14 2021-03-26 湖南大学 一种靶向pd1-pdl1的双特异性核酸适体及其衍生物
KR20200068647A (ko) 2017-08-11 2020-06-15 시티 오브 호프 트랜스페린 수용체 (TfR)에 대한 RNA 앱타머
US11007211B2 (en) * 2018-01-07 2021-05-18 City Of Hope CCR7 aptamers and uses thereof
EP3683310A1 (en) 2019-01-21 2020-07-22 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer and use of the aptamer in the diagnosis and treatment of cancer
CN111154765B (zh) * 2019-12-30 2023-08-01 广西医科大学 T细胞免疫检查点pd-1的适配体筛选、鉴定方法及抗肿瘤应用
WO2021176330A1 (en) 2020-03-03 2021-09-10 Array Biopharma Inc. Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
CN111593053B (zh) * 2020-05-27 2022-02-15 武汉大学 识别人程序性死亡受体1的dna适配体及方法和应用
WO2023070132A1 (en) * 2021-10-22 2023-04-27 Ohio State Innovation Foundation Immunotherapies for the treatment of cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031890A1 (en) * 2001-06-08 2007-02-08 Jay Wohlgemuth Methods and compositions for diagnosing and monitoring transplant rejection
WO2010103292A2 (en) * 2009-03-12 2010-09-16 Brainco Biopharma S.L. A genotyping tool for improving the prognostic and clinical management of ms patients
WO2011099857A1 (en) * 2010-02-11 2011-08-18 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for typing a sample for rheumatoid arthritis or spondyloarthritis
US20130209514A1 (en) * 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
WO2013122720A2 (en) * 2012-02-16 2013-08-22 Syngenta Participations Ag Engineered pesticidal proteins
WO2014071379A1 (en) * 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Dosing and administration of oligonucleotide cancer therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1997031012A1 (en) * 1996-02-22 1997-08-28 The Regents Of The University Of Michigan Gene specific universal mammalian sequence-tagged sites
US20040241651A1 (en) * 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
EP1581548A4 (en) * 2002-11-21 2008-04-23 Archemix Corp MULTIVALENT APTAMER THERAPEUTIC WITH IMPROVED PHARMACODYNAMIC PROPERTIES AND METHOD FOR THE PRODUCTION AND USE THEREOF
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2523260A1 (en) * 2003-04-21 2004-11-04 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2617782A1 (en) * 2005-08-26 2007-03-01 Archemix Corp. Aptamers that bind thrombin with high affinity
DK2363481T3 (en) * 2006-05-05 2017-06-26 Ionis Pharmaceuticals Inc Compounds and methods for modulating gene expression
WO2013012921A2 (en) * 2011-07-20 2013-01-24 University Of Iowa Research Foundation Nucleic acid aptamers
WO2013142255A2 (en) * 2012-03-22 2013-09-26 University Of Miami Multi-specific binding agents
AU2013262656A1 (en) * 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating UTRN expression
AU2013340414B2 (en) * 2012-10-23 2019-05-02 Caris Science, Inc. Aptamers and uses thereof
WO2014082083A1 (en) * 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
EP3169776B1 (en) * 2014-07-14 2025-09-03 The Regents of The University of California Crispr/cas transcriptional modulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031890A1 (en) * 2001-06-08 2007-02-08 Jay Wohlgemuth Methods and compositions for diagnosing and monitoring transplant rejection
WO2010103292A2 (en) * 2009-03-12 2010-09-16 Brainco Biopharma S.L. A genotyping tool for improving the prognostic and clinical management of ms patients
US20130209514A1 (en) * 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
WO2011099857A1 (en) * 2010-02-11 2011-08-18 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for typing a sample for rheumatoid arthritis or spondyloarthritis
WO2013122720A2 (en) * 2012-02-16 2013-08-22 Syngenta Participations Ag Engineered pesticidal proteins
WO2014071379A1 (en) * 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Dosing and administration of oligonucleotide cancer therapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
2013年03月01日，Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors，Eli ilboa et al，Clin Cancer Res; 19(5):1054-1062 *

Also Published As

Publication number Publication date
EP3174985A4 (en) 2018-04-04
US20170218369A1 (en) 2017-08-03
WO2016019270A8 (en) 2016-04-14
WO2016019270A1 (en) 2016-02-04
JP2017523781A (ja) 2017-08-24
EP3174985A1 (en) 2017-06-07
CA2956718A1 (en) 2016-02-04
TW201617449A (zh) 2016-05-16
CN107002083A (zh) 2017-08-01
JP6680760B2 (ja) 2020-04-15
US10329570B2 (en) 2019-06-25
KR20170055474A (ko) 2017-05-19

Similar Documents

Publication Publication Date Title
TWI703214B (zh) 具拮抗ｐｄ-１功能的適體分子於癌症治療相關之應用
TWI721008B (zh) 具拮抗ｐｄｌ１功能的適體分子於癌症治療之應用
US20220054633A1 (en) Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent
TWI604846B (zh) 拮抗性ｃｔｌａ－４適體及其於增進免疫活性之應用
EP4387674A1 (en) Targeting oncogenic kras with molecular brush-conjugated antisense oligonucleotide
TWI733071B (zh) 治療或診斷ｔｎｆ相關發炎疾病的ｔｎｆ靶向適配體及其用途
CN112654706B (zh) 靶向淋巴细胞活化基因3(lag-3)的核酸适体及其用途

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees